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Summary
Background To date, dementia prediction models have been exclusively developed and tested in high-income countries 
(HICs). However, most people with dementia live in low-income and middle-income countries (LMICs), where 
dementia risk prediction research is almost non-existent and the ability of current models to predict dementia is 
unknown. This study investigated whether dementia prediction models developed in HICs are applicable to LMICs.
Methods Data were from the 10/66 Study. Individuals aged 65 years or older and without dementia at baseline were 
selected from China, Cuba, the Dominican Republic, Mexico, Peru, Puerto Rico, and Venezuela. Dementia incidence 
was assessed over 3–5 years, with diagnosis according to the 10/66 Study diagnostic algorithm. Discrimination and 
calibration were tested for five models: the Cardiovascular Risk Factors, Aging and Dementia risk score (CAIDE); the 
Study on Aging, Cognition and Dementia (AgeCoDe) model; the Australian National University Alzheimer’s Disease 
Risk Index (ANU-ADRI); the Brief Dementia Screening Indicator (BDSI); and the Rotterdam Study Basic Dementia 
Risk Model (BDRM). Models were tested with use of Cox regression. The discriminative accuracy of each model was 
assessed using Harrell’s concordance (c)-statistic, with a value of 0·70 or higher considered to indicate acceptable 
discriminative ability. Calibration (model fit) was assessed statistically using the Grønnesby and Borgan test. 
Findings 11 143 individuals without baseline dementia and with available follow-up data were included in the analysis. 
During follow-up (mean 3·8 years [SD 1·3]), 1069 people progressed to dementia across all sites (incidence rate 24·9 
cases per 1000 person-years). Performance of the models varied. Across countries, the discriminative ability of the 
CAIDE (0·52≤c≤0·63) and AgeCoDe (0·57≤c≤0·74) models was poor. By contrast, the ANU-ADRI (0·66≤c≤0·78), 
BDSI (0·62≤c≤0·78), and BDRM (0·66≤c≤0·78) models showed similar levels of discriminative ability to those of the 
development cohorts. All models showed good calibration, especially at low and intermediate levels of predicted risk. 
The models validated best in Peru and poorest in the Dominican Republic and China.
Interpretation Not all dementia prediction models developed in HICs can be simply extrapolated to LMICs. Further 
work defining what number and which combination of risk variables works best for predicting risk of dementia in 
LMICs is needed. However, models that transport well could be used immediately for dementia prevention research 
and targeted risk reduction in LMICs.
Funding National Institute for Health Research, Wellcome Trust, WHO, US Alzheimer’s Association, and European 
Research Council.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Dementia is a substantial global health issue. Reduction 
in future numbers of dementia cases through effective 
preventive strategies could significantly affect the 
personal and socioeconomic burdens of dementia. WHO 
has recommended that countries urgently develop 
national public health programmes to reduce the impact 
of dementia,1 and has also published specific guidelines 
for governments, policy makers, and care providers to 
develop and deliver a public health approach to dementia 
prevention.2 Such an approach is particularly essential in 
low-income and middle-income countries (LMICs), 
which are home to about two-thirds of the people living 
with dementia globally, but have lower availability of the 
resources needed to cope with dementia-related care 
compared with high-income countries (HICs). For 
research to move rapidly towards prevention, and 
eventually to limit the expected increase in dementia 
rates in LMICs, it is necessary to establish methods for 
early and accurate identification of individuals at high 
risk of future dementia.
More than 20 different models for predicting dementia 
risk have been developed in HICs.3–5 Predictive accuracy, 
measured using the concordance (c)-statistic (a measure 
of the probability that a randomly selected person with 
the outcome of interest has a higher risk of the outcome 
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than a randomly selected person who did not experience 
the outcome of interest), has been found to range from 
poor (c=0·48)6 to high (c=0·91).7 Very few models have 
been externally validated and, where tested, results have 
been mixed and limited to assessment in HICs only.8,9 
Methodological differences, such as time of testing (eg, 
mid-life [45–64 years] vs later life [≥65 years]) or length of 
follow-up, as well as differing population characteristics 
(eg, age and distribution of risk factors) between the 
development and validation samples probably account 
for the poor external validity.8,9
It is unknown whether models developed in HICs 
are applicable and accurate for dementia risk prediction 
in LMICs. Therefore, we aimed to externally validate 
dementia prediction models developed in HICs by 
applying them in LMICs, including sites in Latin America, 
the Caribbean, and China, using data from the 10/66 
Study.10,11
Methods
Study design and participants
Data were from the 10/66 Study, the protocols for which 
have been published elsewhere.10,11 At baseline, one-phase 
population-based surveys (2004–06 in all sites except 
Puerto Rico, where baseline was 2007–10) of all 
individuals aged 65 years or older, living in geographically 
defined catchment areas in ten countries (Brazil, China, 
Cuba, Dominican Republic, India, Mexico, Nigeria, Peru, 
Puerto Rico, and Venezuela), were conducted. Sample 
size ranged from 1900 to 3000 across countries, and 
more than 80% of the target population responded in all 
areas surveyed. At baseline, participants completed a 
comprehensive interview that included information on 
household, sociodemographic, and health status, and a 
physical and neurological exam including the Geriatric 
Mental State (GMS) examination.12 Informants (which 
could include caregivers, co-residents, family, or other 
close contacts) were also interviewed, where available. 
Blood samples were collected in all countries except 
China.
Follow-up interviews were done in seven countries 
(China, Cuba, Dominican Republic, Mexico, Peru, Puerto 
Rico, and Venezuela), at approximately 3–5 years from 
baseline (2007–10 for all countries except Puerto Rico 
where follow-up was 2012–13).10 At follow-up, the baseline 
assessment was repeated. Data from these seven 
countries were used in this analysis.
Participants or their informant (where participants 
lacked the capacity to consent) gave written consent. The 
10/66 Study has institute (Institute of Psychiatry, King’s 
College London, London, UK) and local ethics committee 
approval.11
Selection of risk models for external validation
Dementia prediction models were selected from recent 
systematic reviews3–5 using four criteria: sufficient 
information was published to allow calculation of 
individual risk scores, including predictor weights; 
Research in context
Evidence before this study
Our group has published a number of systematic reviews 
summarising the evidence on the development and testing of 
models for predicting future dementia. These reviews show 
that more than 20 models have been developed for 
predicting risk of future dementia. The discriminative ability 
of the models has been found to be variable (with 
concordance [c]-statistics ranging from 0·48 to 0·91). 
However, model development and testing for dementia risk 
prediction has only been undertaken in high-income 
countries (HICs). Furthermore, where tested, few models have 
been found to have reasonable predictive accuracy outside 
the setting in which they were developed (ie, external 
validity). To date, no external validation studies have been 
undertaken in low-income and middle-income countries 
(LMICs). Therefore, it is unknown whether models derived 
from cohorts in HICs can be applied in LMIC settings.
Added value of this study 
Using data from the 10/66 Study, we investigated whether 
dementia risk prediction models developed in HICs can be 
applied in LMICs without compromise to their level of 
discriminative accuracy. Five models were tested: 
the Cardiovascular Risk Factors, Aging and Dementia risk score 
(CAIDE), the Study on Aging, Cognition and Dementia 
(AgeCoDe) model, the Australian National University 
Alzheimer’s Disease Risk Index (ANU-ADRI), the Brief 
Dementia Screening Indicator (BDSI), and the Rotterdam 
Study Basic Dementia Risk Model (BDRM). The results were 
mixed. The CAIDE and the AgeCoDe models showed poor 
discriminative ability when applied in LMICs. By contrast, in all 
countries, the ANU-ADRI, BDSI, and BDRM showed similar 
performance to when they were mapped in HIC settings. 
The models were well calibrated, especially at low and 
intermediate risk levels.
Implications of all the available evidence 
Current dementia risk prediction models developed in HICs, 
including the ANU-ADRI, BDSI, and BDRM, can be used in 
LMICs without compromise to their discriminative ability. 
Importantly, these models provide an effective and simple way 
of identifying individuals who would benefit from 
intervention to reduce their dementia risk. However, further 
work is needed to undertake model development and testing 
in LMICs to assess whether predictive accuracy and calibration 
can be improved. Such models are necessary to move rapidly 
towards dementia prevention, and eventually limit the 
expected increase in dementia rates in LMICs.
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identical or similar predictor variables were available 
in the 10/66 Study dataset to enable accurate mapping 
of the risk score; the variables included in the risk 
model were simple to attain (eg, we excluded models 
that incorporated neuroimaging data); and the 
predictive accuracy of the model, as reported in the 
development study, was acceptable (defined as a 
c-statistic ≥0·70).13 On the basis of these criteria, five 
models were selected: the Cardiovascular Risk Factors, 
Aging and Dementia (CAIDE) risk score;14 the Aging, 
Cognition and Dementia (AgeCoDe) model;15 the 
Australian National University Alzheimer’s Disease 
Risk Index (ANU-ADRI);16,17 the Brief Dementia 
Screening Indicator (BDSI);18 and the Rotterdam 
Study Basic Dementia Risk Model (BDRM).19 
Table 1 includes full details of each model (see 
appendix 3 [pp 1–2] for information on how the risk 
variables incorporated in the different models were 
assessed in the 10/66 Study).
Outcome
The outcome was incident dementia (all causes), 
diagnosed according to the 10/66 diagnostic algorithm.20 
This probabilistic algorithm incorporates cognitive test 
scores, including the Community Screening Instrument 
for Dementia (CSI-D) COGSCORE and the modified 
Consortium to Establish a Registry for Alzheimer’s 
Disease ten-word list-learning task with delayed recall, as 
well as informant reports of cognitive and functional 
decline from the CSI-D RELSCORE and diagnostic 
output from the GMS examination.12
For the analysis, time to diagnosis was defined as the 
date from the baseline interview to the date of the follow-
up interview when dementia was diagnosed. A pre-
specified sensitivity analysis was completed with time of 
diagnosis defined as the midway point between the 
baseline and follow-up visits. 
Statistical analysis and external validation
All analyses were done with Stata version 15.0. The study 
was conducted and reported in line with the Transparent 
Reporting of a Multivariate Prediction Model for Individual 
Prediction or Diagnosis statement.21
Differences between countries in sociodemographic 
and health variables were compared using ANOVA for 
continuous variables and χ² test for categorical variables.
We computed the individual probabilities for each of 
the five risk models using the original prediction 
algorithms. Full details of how each risk model was 
mapped in the 10/66 Study, including the scores allocated 
to each variable, are shown in the appendix 3 (pp 3–5). As 
blood samples were not collected in China, information 
on total cholesterol (required for mapping the CAIDE 
and ANU-ADRI scores) was unavailable. Therefore, the 
CAIDE and ANU-ADRI models were mapped in China 
without cholesterol data.
Cox proportional hazards regression was used to test 
each model. Cox regression was chosen to allow us to 
account for time to event and censoring (ie, death and 
dropout). Time on the study was taken as the time from 
the baseline assessment to diagnosis of dementia, 
end of follow-up, or death or dropout, whichever 
came first. We used the Schoenfeld residuals test to 
check the proportional hazards assumption and found 
no violations. Discriminative accuracy was assessed 
using Harrell’s c-statistic. Calibration, or model fit, was 
assessed statis tically using the Grønnesby and Borgan 
(GB) test and graphically using Cox-Snell residual plots. 
Models were tested in each country separately. In order 
to quantify overall (average) predictive performance and 
hetero geneity (I² statistic)22 in predictive performance 
across the different countries, we also combined the 
c-statistic outputs with use of a random-effects meta-
analysis.23
Individuals with missing data were excluded. 
Total sample Country-specific data p value
Cuba Dominican 
Republic 
Peru Venezuela Mexico Puerto Rico China 
Cohort characteristics 
Sample size at baseline 15 016 2944 2011 1933 1965 2003 1998 2162 ··
Dementia at baseline 1429/15 016 
(9·5%)
323/2944 
(11·0%)
242/2011 
(12·0%)
166/1933 
(8·6%)
145/1965 
(7·4%)
180/2003 
(9·0%)
233/1998 
(11·7%)
140/2162 
(6·5%)
··
Missing follow-up status 2444/15 016 
(16·3%)
321/2944 
(10·9%)
328/2011 
(16·3%)
444/1933 
(23·0%)
467/1965 
(23·8%)
302/2003 
(15·1%)
392/1998 
(19·6%)
190/2162 
(8·8%)
··
Sample used for analysis 11 143/15 016 
(74·2%)
2300/2944 
(78·1%)
1441/2011 
(71·7%)
1323/1933 
(68·4%)
1353/1965 
(68·9%)
1521/2003 
(75·9%)
1373/1998 
(68·7%)
1832/2162 
(84·7%)
··
Follow-up status
Mean follow-up time, years 3·8 (1·2) 4·0 (1·3) 4·3 (1·5) 3·0 (0·8) 3·9 (1·1) 2·8 (0·6) 4·0 (1·2) 4·4 (1·2) <0·0001
Dementia at follow-up 1069/11 143 
(9·6%)
182/2300 
(7·9%)
165/1441 
(11·5%)
77/1323 
(5·8%)
155/1353 
(11·5%)
130/1521 
(8·5%)
153/1373 
(11·1%)
207/1832 
(11·3%)
<0·0001
Deceased at follow-up 1709/11 143 
(15·3%)
437/2300 
(19·0%)
323/1441 
(22·4%)
101/1323 
(7·6%)
141/1353 
(10·4%)
157/1521 
(10·3%)
170/1373 
(12·4%)
380/1832 
(20·7%)
<0·0001
(Table 2 continues on next page)
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Total sample Country-specific data p value
Cuba Dominican 
Republic 
Peru Venezuela Mexico Puerto Rico China 
(Continued from previous page)
Demographic characteristics at baseline*
Sex <0·0001
Female 6973/11 137 
(62·6%)
1480/2300 
(64·4%)
948/1439 
(65·9%)
791/1323 
(59·8%)
849/1353 
(62·7%)
963/1521 
(63·3%)
923/1369 
(67·4%)
1019/1832 
(55·6%)
··
Male 4164/11 137 
(37·4%)
820/2300 
(35.7%)
491/1439 
(34·1%)
532/1323 
(40·2%)
504/1353 
(37·3%)
558/1521 
(36·7%)
446/1369 
(32·6%)
813/1832 
(44·4%)
··
Age, years 73·8 (6·6) 74·4 (6·6) 74·6 (7·2) 74·2 (7·0) 71·8 (6·4) 73·6 (6·2) 75·4 (6·5) 72·8 (5·9) ··
Education <0·0001
Primary school not completed 4468/11 107 
(40·2%)
531/2295 
(23·1%)
1019/1435 
(71·0%)
256/1313 
(19·5%)
391/1344 
(29·1%)
1047/1519 
(68·9%)
273/1369 
(19·9%)
951/1832 
(51·9%)
··
Completed primary school 3231/11 107 
(29·1%)
771/2295 
(33·6%)
266/1435 
(18·5%)
493/1313 
(37·5%)
683/1344 
(50·8%)
286/1519 
(18·8%)
260/1369 
(19·0%)
472/1832 
(25·8%)
··
Completed secondary, tertiary, or 
further school
3408/11 107 
(30·7%)
993/2295 
(43·3%)
150/1435 
(10·5%)
564/1313 
(43·0%)
270/1344 
(20·1%)
186/1519 
(12·2%)
836/1369 
(61·1%)
409/1832 
(22·3%)
··
Marital status <0·0001
Married 5656/11 105 
(50·9%)
1019/2294 
(44·4%)
451/1433 
(31·5%)
777/1316 
(59·0%)
681/1341 
(50·8%)
798/1520 
(52·5%)
717/1369 
(52·4%)
1213/1832 
(66·21%)
··
Unmarried 5449/11 105 
(49·1%)
1275/2294 
(55·6%)
982/1433 
(68·5%)
539/1316 
(41·0%)
660/1341 
(49·2%)
722/1520 
(47·5%)
652/1369 
(47·6%)
619/1832 
(33·8%)
··
Lifestyle factors at baseline*
Social engagement  <0·0001
Low 1492/11 143 
(13·4%)
330/2300 
(14·3%)
173/1441 
(12·0%)
92/1323 
(7·0%)
150/1353 
(11·0%)
236/1521 
(15·5%)
225/1373 
(16·4%)
286/1832 
(15·6%)
··
Low to medium 3576/11 143 
(32·1%)
741/2300 
(32·2%)
432/1441 
(30·0%)
278/1323 
(21·0%)
359/1353 
(26·5%)
455/1521 
(29·9%)
373/1373 
(27·2%)
938/1832 
(51·2%)
··
Medium to high 3667/11 143 
(32·9%)
784/2300 
(34·1%)
544/1441 
(37·8%)
448/1323 
(33·9%)
468/1353 
(34·6%)
507/1521 
(33·3%)
384/1373 
(28·0%)
532/1832 
(29·0%)
··
High 2408/11 143 
(21·6%)
445/2300 
(19·3%)
292/1441 
(20·3%)
505/1323 
(38·2%)
376/1353 
(27·8%)
323/1521 
(21·2%)
391/1373 
(28·5%)
76/1832 
(4·1%)
··
Smoking <0·0001
Never 7140/11 100 
(64·3%)
1229/2294 
(53·6%)
751/1439 
(52·2%)
1095/1319 
(83·0%)
729/1326 
(55·0%)
1039/1521 
(68·3%)
999/1369 
(73·0%)
1298/1832 
(70·9%)
··
Ever 2478/11 100 
(22·3%)
614/2294 
(26·8%)
508/1439 
(35·3%)
177/1319 
(13·4%)
445/1326 
(33·6%)
345/1521 
(22·7%)
298/1369 
(21·8%)
91/1832 
(5·0%)
··
Current 1482/11 100 
(13·4%)
451/2294 
(19·7%)
180/1439 
(12·5%)
47/1319 
(3·6%)
152/1326 
(11·5%)
137/1521 
(9·0%)
72/1369 
(5·3%)
443/1832 
(24·2%)
··
Light or moderate alcohol intake 1004/10 486 
(9·6%)
201/2267 
(8·9%)
81/1431 
(5·7%)
59/1289 
(4·6%)
207/791 
(26·2%)
258/1509 
(17·1%)
129/1367 
(9·4%)
69/1832 
(3·8%)
<0·0001
Fish intake <0·0001
Never 1596/11 095 
(14·4%)
198/2294 
(8·6%)
480/1430 
(33·6%)
102/1320 
(7·7%)
57/1333 
(4·3%)
414/1517 
(27·3%)
307/1369 
(22·4%)
38/1832 
(2·1%)
··
Some days 7547/11 095 
(68·0%)
1859/2294 
(81·0%)
834/1430 
(58·3%)
959/1320 
(72·7%)
596/1333 
(44·7%)
1027/1517 
(67·7%)
1038/1369 
(75·8%)
1234/1832 
(67·4%)
··
Most days 1843/11 095 
(16·6%)
229/2294 
(10·0%)
110/1430 
(7·7%)
224/1320 
(17·0%)
646/1333 
(48·5%)
74/1517 
(4·9%)
24/1369 
(1·8%)
536/1832 
(29·3%)
··
Every day 109/11 095 
(1·0%)
8/2294 
(0·3%)
6/1430 
(0·4%)
35/1320 
(2·7%)
34/1333 
(2·6%)
2/1517 
(0·1%)
0/1369 24/1832 
(1·3%)
··
Physically active <0·0001
Not (very) 3736/11 090 
(33·7%)
636/2291 
(27·8%)
482/1434 
(33·6%)
365/1317 
(27·7%)
444/1333 
(33·3%)
502/1514 
(33·2%)
412/1369 
(30·1%)
895/1832 
(48·9%)
··
Fairly 4681/11 090 
(42·2%)
1030/2291 
(45·0%)
422/1434 
(29·4%)
563/1317 
(42·7%)
642/1333 
(48·2%)
684/1514 
(45·2%)
708/1369 
(51·7%)
632/1832 
(34·5%)
··
Very 2673/11 090 
(24·1%)
625/2291 
(27·3%)
530/1434 
(37·0%)
389/1317 
(29·5%)
247/1333 
(18·5%)
328/1514 
(21·7%)
249/1369 
(18·2%)
305/1832 
(16·6%)
··
(Table 2 continues on next page)
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Role of the funding source
The funders had no role in study design or conduct, data 
collection, data analysis, data interpretation, writing of 
the report, or submission of the manuscript for 
publication. MPrina had full access to all the data. 
BCMS, LR, and MPrina took the decision, in conjunction 
with the coauthors, to submit the manuscript for 
publication.
Total sample Country-specific data p value
Cuba Dominican 
Republic 
Peru Venezuela Mexico Puerto Rico China 
(Continued from previous page)
Health-related factors at baseline*
Obesity (waist-to-height ratio ≥0·63 
[male] or ≥0·58 [female])
4197/10 493 
(40·0%)
739/2267 
(32·6%)
606/1416 
(42·8%)
568/1281 
(44·3%)
468/1063 
(44·0%)
789/1473 
(53·6%)
572/1170 
(48·9%)
455/1823 
(25·0%)
<0·0001
High total cholesterol 785/6962 
(11·3%)
294/1838 
(16·0%)
150/1086 
(13·8%)
42/558 
(7·5%)
159/942 
(16·9%)
69/1329 
(5·2%)
71/1209 
(5·9%)
NA <0·0001
High systolic blood pressure 3301/10 681 
(30·9%)
1229/2296 
(53·5%)
416/1430 
(29·1%)
74/1321 
(5·6%)
379/1096 
(34·6%)
349/1518 
(23·0%)
277/1192 
(23·2%)
577/1828 
(31·6%)
<0·0001
Diabetes 1926/11 108 
(17·3%)
429/2289 
(18·7%)
215/1437 
(15·0%)
127/1317 
(9·6%)
198/1345 
(14·7%)
346/1520 
(22·8%)
445/1369 
(32·5%)
166/1831 
(9·1%)
<0·0001
Stroke 678/11 111 
(6·1%)
151/2294 
(6·6%)
99/1438 
(6·9%)
83/1317 
(6·3%)
81/1341 
(6·0%)
98/1521 
(6·4%)
94/1368 
(6·9%)
72/1832 
(3·9%)
0·0040
Traumatic brain injury 965/11 092 
(8·7%)
125/2290 
(5·5%)
151/1439 
(10·5%)
184/1316 
(14·0%)
194/1325 
(14·6%)
237/1521 
(15·6%)
65/1369 
(4·7%)
9/1832 
(0·5%)
<0·0001
Depressive symptoms 1758/11 143 
(15·8%)
289/2300 
(12·6%)
349/1441 
(24·2%)
253/1323 
(19·1%)
223/1353 
(16·5%)
381/1521 
(25·0%)
252/1373 
(18·4%)
11/1832 
(0·6%)
<0·0001
Physical function at baseline*
Needs help with handling money 323/11 106 
(2·9%)
63/2275 
(2·8%)
82/1441 
(5·7%)
40/1321 
(3·0%)
52/1352 
(3·8%)
47/1519 
(3·1%)
24/1372 
(1·7%)
15/1826 
(0·8%)
<0·0001
One or more reported difficulties with 
ADL or IADL
1950/11 143 
(17·5%)
320/2300 
(13·9%)
388/1441 
(26·9%)
162/1323 
(12·2%)
280/1353 
(20·7%)
392/1521 
(25·8%)
280/1373 
(20·4%)
128/1832 
(7·0%)
<0·0001
Cognition at baseline*
Subjective memory impairment (GMS 
score)
<0·0001
0 4430/11 110 
(39·9%)
790/2296 
(34·4%)
440/1441 
(30·5%)
360/1319 
(27·3%)
517/1346 
(38·4%)
546/1518 
(36·0%)
486/1370 
(35·5%)
1291/1820 
(70·9%)
··
1–3 5515/11 110 
(49·6%)
1227/2296 
(53·4%)
791/1441 
(54·9%)
795/1319 
(60·3%)
626/1346 
(46·5%)
808/1518 
(53·2%)
777/1370 
(56·7%)
491/1820 
(27·0%)
··
>3 1165/11 110 
(10·5%)
279/2296 
(12·2%)
210/1441 
(14·6%)
164/1319 
(12·4%)
203/1346 
(15·1%)
164/1518 
(10·8%)
107/1370 
(7·8%)
38/1820 
(2·1%)
··
Verbal fluency (<18 animals) 7125/11 143 
(63·9%)
1377/2300 
(59·9%)
1155/1441 
(80·2%)
755/1323 
(57·1%)
644/1353 
(47·6%)
1109/1521 
(72·9%)
1082/1373 
(78·8%)
1003/1832 
(54·7%)
<0·0001
Delayed recall <0·0001
7–10 words 2244/11 143 
(20·1%)
519/2300 
(22·6%)
160/1441 
(11·1%)
237/1323 
(17·9%)
334/1353 
(24·7%)
188/1521 
(12·4%)
221/1373 
(16·1%)
585/1832 
(31·9%)
··
5–6 words 3870/11 143 
(34·7%)
936/2300 
(40·7%)
485/1441 
(33·7%)
466/1323 
(35·2%)
514/1353 
(38·0%)
511/1521 
(33·6%)
450/1373 
(32·8%)
508/1832 
(27·7%)
··
0–4 words 5029/11 143 
(45·1%)
845/2300 
(36·7%)
796/1441 
(55·2%)
620/1323 
(46·9%)
505/1353 
(37·3%)
822/1521 
(54·0%)
702/1373 
(51·1%)
739/1832 
(40·3%)
··
Clinical dementia rating24
0 (no dementia) 6749/11 143 
(60·6%)
1468/2300 
(63·8%)
693/1441 
(48·1%)
919/1323 
(69·5%)
749/1353 
(55·4%)
775/1521 
(51·0%)
854/1373 
(62·2%)
1291/1832 
(70·5%)
<0·0001
0·5 4190/11 143 
(37·6%)
800/2300 
(34·8%)
688/1441 
(47·7%)
375/1323 
(28·3%)
580/1353 
(42·9%)
713/1521 
(46·9%)
504/1373 
(36·7%)
530/1832 
(29·0%)
··
1 (mild dementia) 200/11 143 
(1·8%)
31/2300 
(1·3%)
57/1441 
(4·0%)
29/1323 
(2·2%)
24/1353 
(1·8%)
33/1521 
(2·2%)
15/1373 
(1·1%)
11/1832 
(0·6%)
··
2 (moderate dementia) 4/11 143 
(<0·1%)
1/2300 
(<0·1%)
3/1441 
(0·2%)
0/1323 0/1353 0/1521 0/1373 0/1832 ··
Data are n/N (%), where N is the number of participants with non-missing data, or mean (SD). ADL=activities of daily living. GMS=Geriatric Mental State examination. IADL=instrumental activities of daily living. 
NA=not available. *Baseline characteristics were calculated for the participants without baseline dementia. 
Table 2: Baseline characteristics 
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Results
At baseline, 15 016 participants were recruited, of whom 
1429 with prevalent dementia and 2444 who were not 
seen at follow-up were excluded. Thus, the analysed 
sample included 11 143 participants (6973 [62·6%] 
women and 4164 [37·4%] men [of 11 137 with non-missing 
data]), with a mean age of 73·8 years (SD 6·6; 
range 65–106). There were significant differences in the 
sociodemographic characteristics of the samples across 
the different study sites at baseline (table 2). 
Participants were re-interviewed at a mean of 3·8 years 
(SD 1·2; range 1 month to 7·4 years) follow-
up. The number of incident dementia cases in the 
total sample was 1069 (incidence rate 24·9 cases 
per 1000 person-years), with higher rates in China 
(207 cases; 25·3 per 1000 person-years), the Dominican 
Republic (165 cases; 26·3 per 1000 person-years), 
Venezuela (155 cases; 29·0 per 1000 person-years), 
Puerto Rico (153 cases; 27·4 per 1000 person-years), and 
Mexico (130 cases; 30·5 per 1000 person-years), and lower 
rates in Cuba (182 cases; 19·5 per 1000 person-years) and 
Peru (77 cases; 19·3 per 1000 person-years).
With the exception of cholesterol, the proportion of 
missing data was low for all variables (ranging from 
0·1% for age to 5·9% for alcohol; appendix 3 p 6). Data 
on cholesterol, which is needed to calculate the CAIDE 
and ANU-ADRI scores, was missing in 4181 (37·5%) 
individuals, largely because blood samples were not 
collected in China.
The discriminative performance of each of the five 
models when mapped in each country is shown in 
figure 1 (see appendix 3 [p 7] for the full results). 
Compared with the discriminative performance in the 
development cohorts, discrimination performance was 
poor with the CAIDE (0·52≤c≤0·63 across study sites vs 
c=0·77 in the development cohort) and AgeCoDe 
(0·57≤c≤0·74 vs c=0·84) models, particularly when 
mapped in the Dominican Republic and China. By 
contrast, discrimination of the BDSI (0·62≤c≤0·78 
across study sites vs 0·68≤c≤0·78 in the development 
cohorts), ANU-ADRI (0·66≤c≤0·78 vs 0·65≤c≤0·73), and 
BDRM (0·66≤c≤0·78 vs 0·75≤c≤0·78) tended to be at a 
similar level to that reported in the development cohorts 
in HICs. Across countries, the models consistently 
worked better at predicting risk of dementia in Peru and 
Figure 1: Comparison of the predictive accuracy of each model when mapped 
in the 10/66 Study compared with the development cohort(s)
c-statistics for the original studies are shown in green. The dashed line indicates the 
cutoff value for acceptable predictive accuracy (c-statistic ≥0·70). AgeCoDe=Study 
on Aging, Cognition and Dementia. ANU-ADRI=Australian National University 
Alzheimer’s Disease Risk Index. BDRM=Rotterdam Study Basic Dementia Risk 
Model. BDSI=Brief Dementia Screening Indicator. CAIDE=Cardiovascular Risk 
Factors, Aging and Dementia risk score. CHS=Cardiovascular Health Study. 
CVHS=Cardiovascular Health Cognition Study. c=concordance. 
EPOZ=Epidemiological Prevention Study of Zoetermeer. FHS=Framingham Heart 
Study. HRS=Health and Retirement Survey. KP=Kungsholmen Project. MAP=Rush 
Memory and Aging Project. SALSA=The Sacramento Area Latino Study on Aging.
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worst in the Dominican Republic and China. Figure 2 
shows the three models with the highest predictive 
accuracy for dementia in each of the 10/66 Study sites.
In terms of calibration, using the GB test, all models 
showed good calibration (p>0·05), with the exception of 
the ANU-ADRI (χ²=21·4, p=0·011) and BDSI (χ²=18·9, 
p=0·026) when mapped in Puerto Rico and the BDRM 
when mapped in all countries, where the results of the GB 
test suggested that fit was poor. The Cox-Snell residual 
plots for each risk model when mapped across the different 
countries are shown in the appendix 3 (pp 14–18). Models 
generally showed a good fit at low and intermediate risk. 
However, at high risk, predicted values were extreme, 
either leading to underestimation or overestimation in 
most models, particularly for the BDRM and BDSI.
In a meta-analysis, the pooled results for each model 
showed similar predictive accuracy when mapped in 
the individual countries compared with the total sample 
(figure 3). However, the results suggested large hetero-
geneity across countries for the AgeCoDe model 
(I²=80·5%) and BDRM (I²=68·9%). Heterogeneity in the 
other models was low (I² range 0·0–51·1%; figure 3).
In sensitivity analyses, we found no significant 
differences between the sociodemographic or health 
characteristics of individuals included in the analysis and 
those recruited but excluded from the analysis. In 
addition, defining the time of diagnosis as the midway 
point between the baseline and follow-up visits did not 
affect the outcomes (data not shown).
Discussion
In this study, we externally validated five dementia risk 
prediction models, developed and tested in HICs, in 
seven LMICs using data from the 10/66 Study from sites 
in China, Cuba, the Dominican Republic, Mexico, Peru, 
Puerto Rico, and Venezuela. The results indicate that 
while some models (ANU-ADRI, BDSI, and BDRM) 
transported well from HICs to LMICs, others (CAIDE 
and AgeCoDe) did not. Results also varied by country, 
with the highest predictive accuracy reported in Peru and 
the lowest in China and the Dominican Republic. Given 
the increasing interest in dementia prevention, par-
ticularly in LMICs where resources are limited, it is 
essential to develop accurate and valid methods for 
successful prediction of dementia risk to ensure that the 
right people are targeted for intervention.
The CAIDE and AgeCoDe models did not replicate well 
when mapped in the different countries from the 10/66 
Study. With regard to the CAIDE model, this poor 
replication is probably due to methodological and sample 
characteristic differences between the original develop-
ment study and the 10/66 Study (see appendix 3 [p 8] for a 
comparison of the sample characteristics across the 
CAIDE and 10/66 studies). Indeed, the CAIDE score was 
designed to assess mid-life risk (model development 
sample age range 39–64 years), with prediction over a 
mean follow-up period of 20·9 years (SD 4·9). By 
contrast, the 10/66 Study sample was older (age range 
65–106 years) with a mean follow-up of 3·8 years (1·2). 
Figure 2: Discrimination accuracy of models by study site
The three models with the highest accuracy at each site, and their respective c-statistics, are shown. AgeCoDe=Study on Aging, Cognition and Dementia. 
ANU-ADRI=Australian National University Alzheimer’s Disease Risk Index. BDRM=Rotterdam Study Basic Dementia Risk Model. BDSI=Brief Dementia Screening 
Indicator. c=concordance.
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The results here support previous external validation 
studies of the CAIDE score that have shown good trans-
portability within a middle-aged cohort,25 and poor trans-
portability when applied in cohorts of older participants.9,17
With regard to the AgeCoDe model, although the 
follow-up periods were similar between the original 
study and our study, the AgeCoDe sample was older (all 
participants were aged ≥75 years) and had higher 
educational attainment overall than the 10/66 Study 
sample (see appendix 3 [p 9] for a comparison of the 
sample characteristics across the AgeCoDe and 10/66 
studies). Poor prediction using the AgeCoDe score could 
therefore be because the associations between risk 
factors or protective factors and incident dementia are 
age-dependent and education-dependent, such that the 
importance of the different risk and protective factors 
depends on the time of testing26 and the sample 
characteristics (ie, HIC vs LMIC). The AgeCoDe score 
incorporates demographic (age), cognitive function 
(subjective memory impairment, memory function, and 
global cognitive function), and physical status (impair-
ments in instrumental activities of daily living) variables. 
Although these variables might be important for 
predicting dementia in very late life, the model fails to 
capture health (ie, cardiometabolic and cerebrovascular), 
lifestyle (ie, smoking, diet, and alcohol use), and socio-
demographic (ie, deprivation) factors that have been 
found to be important predictors of dementia in mid-life 
to early-late life14 and in LMICs. Furthermore, given that 
cognitive variables were the main predictors in the 
models, the poor predictive performance might have 
been because the 10/66 Study sample was characterised 
Figure 3: Predictive accuracies of each model according to random-effects meta-analyses
AgeCoDe=Study on Aging, Cognition and Dementia. ANU-ADRI=Australian National University Alzheimer’s Disease Risk Index. BDRM=Rotterdam Study Basic Dementia 
Risk Model. BDSI=Brief Dementia Screening Indicator. CAIDE=Cardiovascular Risk Factors, Aging, and Dementia risk score. c=concordance.
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by low educational attainment, meaning that cognitive 
test scores might not be as good at discriminating risk in 
this setting because of differing effects.27,28
In contrast to the CAIDE and AgeCoDe models, the 
ANU-ADRI model (which incorporated age, sex, 
education, waist-to-height ratio, diabetes, depression, 
cholesterol level, traumatic brain injury, smoking, alcohol, 
social engagement, physical activity, and fish intake) and 
the BDSI model (which incorporated, education, waist-to-
height ratio, diabetes, stroke, physical function or 
impairment in instrumental activities of daily living, and 
depression) transported well to LMICs, showing similar 
levels of accuracy to that seen in HICs (see appendix 3 
[pp 10–12] for a comparison of the sample characteristics 
across the 10/66 Study and studies used for the initial 
development and testing of the ANU-ADRI and BDSI). 
These models were also found to be well calibrated. 
Overall, these models include similar predictors such as 
demographics, mental health, and cardiometabolic status, 
suggesting that, as in HICs, these factors add relevant 
information for dementia prediction in LMICs (table 3).
Regarding the BDRM results, the discriminant accuracy 
of this model was in an acceptable range (c-statistic ≥0·70) 
and similar to that reported in the original development 
study. Compared to the other models tested, the BDRM 
has fewer predictors incorporating age, subjective memory 
impairment, history of stroke, and interference with 
finances and medications. Despite having a small number 
of predictors, this model could be performing well because 
it uses the best possible combination of risk variables. 
However, despite reasonable discriminative accuracy, the 
GB calibration test showed that the model did not fit well 
across the different countries (see appendix 3 [p 13] for a 
comparison of the sample characteristics across the 
Rotterdam Study, Epidemiological Prevention Study of 
Zoetermeer, and 10/66 Study). Poor calibration could be 
due to the small sample sizes in some of the risk quantiles; 
the GB calibration test uses deciles to create risk groups 
and we found fewer than five individuals for some risk 
quantiles. Modification of the group size could improve 
calibration. Furthermore, the results from the calibration 
plots indicate that, although the predicted risks at low and 
intermediate levels were acceptable, like the other models, 
they were particularly miscalibrated at high risk levels. 
Finally, the BDRM was designed to predict 10-year risk of 
dementia, whereas in the 10/66 Study prediction was over 
a much shorter period.
Overall, the results suggest that additional work is 
needed to identify the best combination of predictive 
variables and the optimum scores for each variable to 
increase the accuracy of predicting dementia in LMICs. 
As a start, the ANU-ADRI, BDSI, and BDRM models 
show promise. These models have a number of strengths. 
First, they incorporate variables that are easy to measure 
and do not require specialised training to collect. Second, 
the small number of included predictors enhances their 
clinical feasibility and potential uptake in LMIC settings.
The models did not perform equally well across 
countries, with large differences in predictive accuracy 
across the different sites. Overall, the models had the 
highest accuracy for predicting dementia in Peru and 
lowest in China and the Dominican Republic, suggesting 
that the predictor variables (and their combination to 
produce risk scores) incorporated in the different models 
are not robust indicators of future dementia risk across 
all LMIC settings. It is difficult to determine what is 
driving the inter-country differences. Although all sites 
were in LMICs, the countries differ culturally and have 
different disease risk profiles, age profiles, mortality rates, 
life expectancies, views on health and ageing, and political 
and economic systems (including health spending). Even 
across countries such as Peru and the Dominican 
Republic, there are considerable differences (eg, in health 
systems, life expectancy, and education levels). Indeed, 
the Dominican Republic has the lowest levels of education 
AgeCoDE CAIDE BDSI ANU-
ADRI
BDRM
Age Yes Yes Yes Yes Yes
Sex ·· Yes ·· Yes  ··
Subjective memory 
impairment 
Yes ·· ·· ·· Yes
Verbal fluency Yes ·· ·· ·· ··
Delayed recall Yes ·· ·· ·· ··
Mini-Mental State 
Examination
Yes ·· ·· ·· ··
Instrumental activities of 
daily living
Yes ·· ·· ·· ··
Education ·· Yes Yes Yes ··
Systolic blood pressure ·· Yes ·· ·· ··
Body-mass index ·· Yes Yes Yes ··
Cholesterol ·· Yes ·· Yes ··
Physical activity ·· Yes ·· Yes ··
Diabetes ·· ·· Yes Yes ··
Stroke ·· ·· Yes ·· Yes
Needs help with medication 
or handling money 
·· ·· Yes ·· Yes
Depressive symptoms ·· ·· Yes Yes ··
Traumatic brain injury ·· ·· ·· Yes ··
Cognitive stimulating 
activities
·· ·· ·· Yes ··
Social network ·· ·· ·· Yes ··
Smoking ·· ·· ·· Yes ··
Alcohol ·· ·· ·· Yes ··
Fish intake ·· ·· ·· Yes ··
Pesticide exposure ·· ·· ·· Yes ··
Predictor variables can be measured differently (eg, education is categorical [0–6, 
7–9, and ≥10 years] in CAIDE but binary [<12 and ≥12 years] in BDSI). 
AgeCoDe=Study on Aging, Cognition and Dementia. ANU-ADRI=Australian 
National University Alzheimer’s Disease Risk Index. BDRM=Rotterdam Study Basic 
Dementia Risk Model. BDSI=Brief Dementia Screening Indicator. 
CAIDE=Cardiovascular Risk Factors, Aging, and Dementia Risk Score.
Table 3: Predictor variables included in the dementia risk prediction 
models
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across all sites, which might explain some of the 
differences in the results. Furthermore, models might 
not transport well across settings because of the unique 
risk factors for dementia (including low educational 
attainment, socioeconomic status, ethnicity, and poverty) 
in LMICs compared with HICs, which need to be 
considered when determining risk in LMICs. The 
findings could indicate that the models are country-
specific and need to be recalibrated to the new setting. 
Indeed, the combination of risk factors in each model 
might be appropriate, but the weighting (or risk score) 
assigned to each factor might need to be adjusted across 
the different countries. For instance, in the BDSI, a score 
of 6 is assigned to history of stroke, but in LMICs the 
score might need to be greater (or less) than 6. 
Alternatively, it could be that the unique combination of 
factors needs to be adjusted by site (eg, smoking is 
common in China and might not be as sensitive for 
discriminating high-risk vs low-risk cases compared with 
other sites where smoking prevalence is lower). However, 
recalibration and development of new models is beyond 
the scope of this Article, in which the focus is external 
validation.
The strengths of this study include the use of a large 
sample with very few missing data (apart from cholesterol 
data in China) from seven different LMICs, which made 
it possible to test multiple prediction models in different 
countries using the same research methods. There were, 
however, some limitations. First, some adaptations were 
made to the models to enable their calculation in the 
10/66 Study. For example, BMI (required for mapping 
obesity in the CAIDE model and underweight in the 
BDSI model) was missing because weight was not 
measured in the baseline assessment. Instead we used 
waist-to-height ratio, which, despite having been found 
to be a better measure of central adiposity and more 
strongly associated with impaired cardiometabolic 
health,29 meant that the comparisons between studies 
were not identical. In addition, the CAIDE model 
requires knowledge of mid-life health status, which was 
not available in the 10/66 Study. Hence, a more detailed 
assessment of the CAIDE model in LMIC settings using 
information on mid-life risk factors is needed. Second, 
because of restrictions in data availability, we were able to 
test only a limited number of models. As a result, we 
could have missed identifying a model that might have 
validated well, with higher predictive accuracy than 
observed here. Third, our study was restricted to LMICs 
in South America, China, and the Caribbean. Given the 
inter-country differences in model performance, the 
results might therefore not generalise to all LMICs, 
including, for example, LMICs in South Asia, Africa, and 
the Middle East. Further work is needed to extend the 
analysis to other LMICs. Finally, having done a complete-
case analysis might have biased the results by limiting 
their generalisability; however, a sensitivity analysis 
found no differences in the socioeconomic characteristics 
or health status between those included and excluded 
from the study.
As populations continue to age rapidly, the number of 
people with dementia is predicted to rise, with some of the 
biggest increases expected to be seen in LMICs.30 In the 
absence of any curative treatment for dementia, prevention 
and the proactive management of modifiable risk factors 
to delay or slow the onset or progression of the disease are 
key action areas in the WHO Global Action Dementia 
Plan.1 Our findings highlight that the ANU-ADRI, BDSI, 
and BDRM models could be used in LMICs to help 
identify individuals for frequent monitoring and targeted 
dementia risk reduction. However, additional work is 
needed to test these models in other LMICs before 
recommendations can be made regarding the best model 
for use in LMIC settings; and to determine whether model 
refinement enhances dementia risk prediction in LMICs.
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